Results 161 to 170 of about 7,627,804 (319)

Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia   +20 more
wiley   +1 more source

Saliva Based Clozapine Therapeutic Drug Monitoring: A Systematic Review. [PDF]

open access: yesPharmacol Res Perspect
Rademaker T   +4 more
europepmc   +1 more source

Circulating Interleukin‐6 Levels and Timing of Acute Ischemic Stroke Onset

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Intravenous thrombolysis is the most widely available effective ischemic stroke treatment, but is approved only if given within 4.5 h from stroke onset. Many patients are not treated because stroke onset time is unknown. We evaluated the cytokine interleukin 6 (IL‐6) in circulating blood after acute ischemic stroke (AIS).
Robert G. Kowalski   +15 more
wiley   +1 more source

Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2011
Jason D. Arroyo   +11 more
semanticscholar   +1 more source

Multimodal Autonomic Biomarkers Predict Phenoconversion in Pure Autonomic Failure

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Pure autonomic failure (PAF) presents with autonomic failure without other neurological features. A third develop central neurological features, fulfilling criteria for multiple system atrophy (MSA) and Lewy body diseases (LBD), including Parkinson's disease and Dementia with Lewy bodies.
S. Koay   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy